



## Drug Coverage Policy

Effective Date.....12/15/2024

Coverage Policy Number ..... IP0421

Policy Title ..... Fasenra

## Immunologicals – Fasenra

- Fasenra® (benralizumab subcutaneous injection – AstraZeneca)

### INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment and have discretion in making individual coverage determinations. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

## Cigna Healthcare Coverage Policy

### OVERVIEW

Fasenra, an interleukin-5 receptor alpha (IL-5Ra)-directed cytolytic monoclonal antibody, is indicated for the following uses:<sup>1</sup>

- **Asthma** as add-on maintenance treatment of patients ≥ 6 years of age with severe disease and an eosinophilic phenotype. Limitations of Use: Fasenra is not indicated for the treatment of other eosinophilic conditions or for the relief of acute bronchospasm/status asthmaticus.
- **Eosinophilic granulomatosis with polyangiitis (EGPA)** in adults.

## Clinical Efficacy

### *Asthma*

In two pivotal asthma studies, the addition of Fasenra to existing therapy significantly reduced annualized asthma exacerbation rates in patients with baseline blood eosinophil levels  $\geq 300$  cells/microliter.<sup>2-4</sup> The magnitude of the improvements observed with Fasenra in this patient population were larger than those observed in patients with lower baseline eosinophil levels (e.g.,  $< 150$  cells/microliter). Another pivotal study involved adults with severe asthma receiving high-dose inhaled corticosteroid (ICS)/long-acting beta<sub>2</sub>-agonist (LABA) and chronic oral corticosteroid therapy who had a baseline blood eosinophil level  $\geq 150$  cells/microliter.<sup>4</sup>

### *Eosinophilic Granulomatosis with Polyangiitis*

One study evaluated the efficacy of Fasenra in patients  $\geq 18$  years of age with relapsing or refractory EGPA who had received  $\geq 4$  weeks of a stable oral corticosteroid dose (i.e., prednisolone, prednisone, methylprednisolone, or hydrocortisone).<sup>13</sup> The primary endpoint was the proportion of patients in remission at both Week 36 and Week 48.

## Guidelines

The Global Initiative for Asthma Global Strategy for Asthma Management and Prevention (2024) proposes a stepwise approach to asthma treatment.<sup>5</sup> Fasenra is listed as an option for add-on therapy in patients  $\geq 12$  years of age with severe eosinophilic asthma. Severe asthma is defined as asthma that is uncontrolled despite adherence to optimized high-dose ICS/LABA therapy or that worsens when high-dose treatment is decreased. Of note, guidelines have not been updated since the lower age indication of Fasenra was FDA-approved. Higher blood eosinophil levels, higher number of severe exacerbations in the previous year, adult-onset asthma, nasal polyps, maintenance oral corticosteroid requirements, and low lung function may predict a good asthma response to Fasenra.

According to the European Respiratory Society/American Thoracic Society guidelines (2014; updated in 2020), severe asthma is defined as asthma which requires treatment with a high-dose ICS in addition to a second controller medication (and/or systemic corticosteroids) to prevent it from becoming uncontrolled, or asthma which remains uncontrolled despite this therapy.<sup>6,7</sup> Uncontrolled asthma is defined as asthma that worsens upon tapering of high-dose ICS or systemic corticosteroids or asthma that meets one of the following four criteria:

- 1) Poor symptom control: Asthma Control Questionnaire consistently  $\geq 1.5$  or Asthma Control Test  $< 20$ ;
- 2) Frequent severe exacerbations: two or more bursts of systemic corticosteroids in the previous year;
- 3) Serious exacerbations: at least one hospitalization, intensive care unit stay, or mechanical ventilation in the previous year;
- 4) Airflow limitation: forced expiratory volume in 1 second (FEV<sub>1</sub>)  $< 80\%$  predicted after appropriate bronchodilator withholding.

### *Eosinophilic Granulomatosis with Polyangiitis Guidelines*

The American College of Rheumatology (ACR)/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated (ANCA) Vasculitis (2021) includes recommendations regarding the management of EGPA.<sup>14</sup> Fasenra is not addressed. However, for patients with active, non-severe EGPA, combination therapy with an anti-IL-5 agent and a corticosteroid is recommended over other traditional treatments such as methotrexate, azathioprine, or mycophenolate mofetil in the setting of remission induction. Non-severe EGPA is defined as vasculitis in the absence of life- or organ-threatening manifestations. In general, the clinical profile includes rhinosinusitis, asthma, mild systemic symptoms, uncomplicated cutaneous disease, and mild inflammatory arthritis. An anti-IL-5 agent, in combination with corticosteroids, is

also a recommended therapy for patients who have relapsed and are experiencing non-severe disease manifestations (i.e., asthma and/or sinonasal disease) while receiving either low-dose corticosteroids alone, methotrexate, azathioprine, or mycophenolate mofetil. For patients with severe EGPA, cyclophosphamide or rituximab is preferred over an anti-IL-5 agents for remission induction. The European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of ANCA-associated vasculitis (2022) also do not yet address Fasenra.<sup>15</sup> However, similar to the ACR guidelines, EULAR recommends an anti-IL-5 agent for induction of remission in patients with relapsing or refractory EGPA without active organ- or life-threatening disease. It is also recommended for maintenance of remission in these patients. Additionally, it is also among the many recommended treatment options for the maintenance of remission of EGPA after induction of remission for organ-threatening or life-threatening disease.

## Medical Necessity Criteria

**Fasenra is considered medically necessary when the following criteria are met:**

### FDA-Approved Indication

- 1. Asthma.** Approve Fasenra for the duration noted if the patient meets ONE of the following (A or B):
  - A) Initial Therapy.** Approve for 6 months if the patient meets the following (i, ii, iii, iv, v, and vi):
    - i.** Patient is  $\geq 6$  years of age; AND
    - ii.** Patient meets ONE of the following (a or b):
      - a)** Patient has a blood eosinophil level  $\geq 150$  cells per microliter within the previous 6 weeks; OR
      - b)** ~~within 6 weeks~~ Patient has a blood eosinophil level  $\geq 150$  cells per microliter prior to treatment with Fasenra or another monoclonal antibody therapy that may alter blood eosinophil levels; AND  
Note: Examples of monoclonal antibody therapies that may alter blood eosinophil levels include Fasenra, Adbry (tralokinumab-ldrm subcutaneous injection), Cinqair (reslizumab intravenous infusion), Dupixent (dupilumab subcutaneous injection), Ebglyss (lebrikizumab-lbkz subcutaneous injection), Nemludio (nemolizumab-ilto subcutaneous injection), Nucala (mepolizumab subcutaneous injection), Tezspire (tezepelumab-ekko subcutaneous injection), and Xolair (omalizumab subcutaneous injection).
  - iii.** Patient has received at least 3 consecutive months of combination therapy with BOTH of the following (a and b):
    - a)** A medium- or high-dose inhaled corticosteroid; AND
    - b)** At least one additional asthma controller or asthma maintenance medication; AND  
Note: Examples of additional asthma controller or asthma maintenance medications are inhaled long-acting beta<sub>2</sub>-agonists, inhaled long-acting muscarinic antagonists, and monoclonal antibody therapies for asthma (e.g., Cinqair, Dupixent, Ebglyss, Fasenra, Nemludio, Nucala, Tezspire, Xolair). Use of a combination inhaler containing both a medium- or high-dose inhaled corticosteroid and additional asthma controller/maintenance medication(s) would fulfill the requirement for both criteria a and b.
  - iv.** Patient has a history of ONE of the following (a or b):
    - a)** Patient meets BOTH of the following (1 and 2):
      - (1)** Patient has a forced expiratory volume in 1 second (FEV<sub>1</sub>)  $< 80\%$  predicted; AND

Note: The reduced FEV<sub>1</sub> should not be due to smoking-related chronic obstructive pulmonary disease.

**(2)** Patient has an FEV<sub>1</sub>/forced vital capacity (FVC) < 0.80; OR

**b)** Patient meets ONE of the following (1, 2, 3, 4, or 5):

**(1)** Increase of > 12% and > 200ml in FEV<sub>1</sub> following administration of a standard dose of a short-acting bronchodilator; OR

**(2)** Increase of > 12% and > 200ml in FEV<sub>1</sub> between prescriber visits; OR

**(3)** Increase of > 12% and > 200ml in FEV<sub>1</sub> from baseline to after at least 4 weeks of asthma treatment; OR

**(4)** Positive exercise challenge testing; OR

**(5)** Positive bronchial challenge testing; AND

Note: The above lung function criteria may be met at anytime prior to or during asthma treatment.

Note: Patients 6 to 11 years of age would only be required to have an increase of > 12% in FEV<sub>1</sub> in each of the respective criteria above (i.e., they would not be required to have an increase > 200 mL)

**v.** Patient has asthma that is uncontrolled or was uncontrolled at baseline as defined by ONE of the following (a, b, or c):

Note: "Baseline" is defined as prior to receiving Fasenra or another monoclonal antibody therapy for asthma. Examples of monoclonal antibody therapies for asthma include Fasenra, Cinqair, Dupixent, Ebglyss, Nemluvio, Nucala, Tezspire, and Xolair.

**a)** Patient experienced two or more asthma exacerbations requiring treatment with systemic corticosteroids in the previous year; OR

**b)** Patient experienced one or more asthma exacerbation(s) requiring a hospitalization, an emergency department visit, or an urgent care visit in the previous year; OR

**c)** Patient has asthma that worsens upon tapering of oral (systemic) corticosteroid therapy; AND

**vi.** The medication is prescribed by or in consultation with an allergist, immunologist, or pulmonologist.

**B) Patient is Currently Receiving Fasenra.** Approve for 1 year if the patient meets the following (i, ii, and iii):

**i.** Patient has already received at least 6 months of therapy with Fasenra; AND

Note: A patient who has received < 6 months of therapy or who is restarting therapy with Fasenra should be considered under criterion 1A (Asthma, Initial Therapy).

**ii.** Patient continues to receive therapy with one inhaled corticosteroid or one inhaled corticosteroid-containing combination inhaler; AND

**iii.** Patient has responded to therapy as determined by the prescriber.

Note: Examples of a response to Fasenra therapy are decreased asthma exacerbations; decreased asthma symptoms; decreased hospitalizations, emergency department, urgent care, or medical clinic visits due to asthma; and decreased requirement for oral corticosteroid therapy.

**Dosing.** Approve ONE of the following dosing regimens (A or B):

**A)** If the patient weighs < 35 kg, approve the following dosing regimens (i or ii):

**i.** 10 mg administered subcutaneously once every 4 weeks for the first 3 doses; OR

**ii.** 10 mg administered subcutaneously once every 8 weeks; OR

**B)** If the patient weighs ≥ 35 kg, approve the following dosing regimens (i or ii):

**i.** 30 mg administered subcutaneously once every 4 weeks for the first 3 doses; OR

**ii.** 30 mg administered subcutaneously once every 8 weeks.

**2. Eosinophilic Granulomatosis with Polyangiitis (EGPA) [formerly known as Churg-Strauss Syndrome].** Approve Fasenra for the duration noted if the patient meets ONE of the following (A or B):

- A) Initial Therapy.** Approve for 9 months if the patient meets ALL of the following (i, ii, iii, and iv):
- i.** Patient is  $\geq 18$  years of age; AND
  - ii.** Patient has active, non-severe disease; AND  
Note: Non-severe disease is defined as vasculitis without life- or organ-threatening manifestations. Examples of symptoms in patients with non-severe disease include rhinosinusitis, asthma, mild systemic symptoms, uncomplicated cutaneous disease, mild inflammatory arthritis.
  - iii.** Patient meets BOTH of the following (a and b):
    - a)** Patient is currently receiving a systemic corticosteroid (e.g., prednisone) and has been on therapy for a minimum of 4 weeks; AND
    - b)** Patient meets ONE of the following (1 or 2):
      - (1)** Patient has a blood eosinophil level  $\geq 150$  cells per microliter within the previous 4 weeks; OR
      - (2)** Patient had a blood eosinophil level  $\geq 150$  cells per microliter prior to treatment with Fasenra or another monoclonal antibody therapy that may alter blood eosinophil levels; AND  
Note: Examples of monoclonal antibody therapies that may alter blood eosinophil levels include Fasenra, Adbry (tralokinumab-ldrm subcutaneous injection), Cinqair (reslizumab intravenous infusion), Dupixent (dupilumab subcutaneous injection), Ebglyss (lebrikizumab-lbkz subcutaneous injection), Nemluvio (nemolizumab-ilty subcutaneous injection), Nucala (mepolizumab subcutaneous injection), Tezspire (tezepelumab-ekko subcutaneous injection), and Xolair (omalizumab subcutaneous injection).
  - iv.** The medication is prescribed by or in consultation with an allergist, immunologist, pulmonologist, or rheumatologist.
- B) Patient is Currently Receiving Fasenra.** Approve for 1 year if the patient meets BOTH of the following (i and ii):
- i.** Patient has already received at least 9 months of therapy with Fasenra; AND  
Note: A patient who has received  $< 9$  months of therapy or who is restarting therapy with Fasenra should be considered under criterion 2A (Eosinophilic Granulomatosis with Polyangiitis, Initial Therapy).
  - ii.** Patient has responded to therapy as determined by the prescriber.  
Note: Examples of a response to Fasenra therapy are reduced rate of relapse, corticosteroid dose reduction, and reduced eosinophil levels.

**Dosing.** Approve 30 mg administered subcutaneously once every 4 weeks.

When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.

Receipt of sample product does not satisfy any criteria requirements for coverage.

## Conditions Not Covered

Any other use is considered experimental, investigational, or unproven, including the following (this list may not be all inclusive; criteria will be updated as new published data are available):

1. **Chronic Obstructive Pulmonary Disease (COPD).** Fasenra is not indicated for the treatment of COPD.<sup>1</sup> One double-blind, placebo-controlled, Phase IIa study (n = 101)

evaluated the efficacy and safety of Fasenra in patients 40 to 80 years of age with eosinophilia and moderate to severe COPD.<sup>8</sup> The annualized rate of acute COPD exacerbations was not reduced with Fasenra compared with placebo. Lung function was also not significantly improved with Fasenra vs. placebo. Numerically greater (although non-significant) improvements in exacerbations and lung function were observed with Fasenra vs. placebo in patients with baseline blood eosinophil levels of 200 cells/microliter or more. Two double-blind, placebo-controlled, Phase III studies (GALATHEA and TERRANOVA) also evaluated Fasenra in patients with moderate to very severe COPD (n = 1,120 and n = 1,545 patients, respectively, with eosinophils  $\geq$  220 cells/mm<sup>3</sup>).<sup>9</sup> Following, 56 weeks of therapy, the annualized COPD exacerbation rates were not statistically significantly reduced with Fasenra vs. placebo in either study. Current COPD guidelines from the Global Initiative for Chronic Lung Disease (2024) note the negative data with Fasenra and state that further studies are needed.<sup>10</sup>

2. **Concurrent use of Fasenra with another Monoclonal Antibody Therapy.** The efficacy and safety of Fasenra used in combination with other monoclonal antibody therapies have not been established.

Note: Monoclonal antibody therapies are Adbry® (tralokinumab-ldrm subcutaneous injection), Cinqair® (reslizumab intravenous infusion), Dupixent® (dupilumab subcutaneous injection), Ebglyss (lebrikizumab-lbkz subcutaneous injection), Nemlurio (nemolizumab-ilto subcutaneous injection), Nucala® (mepolizumab subcutaneous injection), Teszipire® (tezepelumab-ekko subcutaneous injection), or Xolair® (omalizumab subcutaneous injection).

3. **Hypereosinophilic Syndrome.** Fasenra is not indicated for the treatment of eosinophilic conditions other than asthma.<sup>1</sup> A small, randomized, double-blind, placebo-controlled, Phase II trial (n = 20) evaluated the efficacy of Fasenra in patients who had platelet-derived growth factor receptor alpha (PDGFRA)-negative hypereosinophilic syndrome with an absolute eosinophil count of 1,000 cells/mm<sup>3</sup>.<sup>11</sup> At Week 12, 90% of patients receiving Fasenra (n = 9/10) vs. 30% of patients receiving placebo (n = 3/10) achieved a 50% or greater reduction in the absolute eosinophil count (P = 0.02). Following the randomized phase, all patients received open-label Fasenra 30 mg every 4 weeks. During this time, 74% of patients (n = 14/19) had sustained clinical and hematologic responses for 48 weeks. The World Health Organization (WHO) and international consensus classification of eosinophilic disorders update on diagnosis, risk stratification, and management (2024) acknowledges that Fasenra has been studied in patients with hypereosinophilic syndrome.<sup>12</sup> A Phase III study of Fasenra in this patient population is currently underway, with primary completion anticipated in May 2024. At this time, the WHO notes that Fasenra remains investigational. Available data with Fasenra is discussed, but this therapy continues to be considered investigational.

## Coding Information

### Note:

- 1) This list of codes may not be all-inclusive.
- 2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

HCPCS Codes	Description
J0517	Injection, benralizumab, 1 mg

## References

1. Fasenra® subcutaneous injection [prescribing information]. Wilmington, DE: AstraZeneca; April 2024.
2. Bleecker ER, Fitzgerald JM, Chanez P, et al. Efficacy and safety of Fasenra for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting  $\beta_2$ -agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. *Lancet*. 2016; 388:2115-2127.
3. Fitzgerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor  $\alpha$  monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomized, double-blind, placebo-controlled phase 3 trial. *Lancet*. 2016; 388:2128-2141.
4. Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. *N Engl J Med*. 2017;376(25):2448-2458.
5. Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2023. Available at: <http://www.ginasthma.org>. Accessed on: April 9, 2024.
6. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation, and treatment of severe asthma. *Eur Respir J*. 2014; 43:343-373.
7. Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society Guideline. *Eur Respir J*. 2020; 55:1900588.
8. Brightling CE, Bleecker ER, Panettieri RA, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomized, double-blind, placebo-controlled, phase 2a study. *Lancet Respir Med*. 2014;2(11):891-901.
9. Criner GJ, Celli BR, Brightling CE, et al. Benralizumab for the prevention of COPD exacerbations. *N Engl J Med*. 2019;381(11):1023-1034.
10. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2024 report. Global Initiative for Chronic Obstructive Lung Disease, Inc. Available from: <http://goldcopd.org/>. Accessed on April 9, 2024.
11. Kuang FL, Legrand F, Mikiya M, et al. Benralizumab for PDGFRA-negative hypereosinophilic syndrome. *N Engl J Med*. 2019;380(14):1336-1346.
12. Shomali W, Gotlib J. World Health Organization, and international consensus classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management. *Am J Hematol*. 2024;99(5):946-968.

## Revision Details

Type of Revision	Summary of Changes	Date
Annual Revision	<p><b>Policy Name Change: Updated</b> Policy Name from "Benralizumab" to "Immunologicals – Fasenra."</p> <p><b>Asthma:</b> Age of approval was reduced from <math>\geq 12</math> years of age to <math>\geq 6</math> years of age. <b>Updated</b> diagnostic criteria requirements for confirmation of asthma. <b>Added</b> dosing information.</p> <p><b>Authorization Duration: Updated</b> initial therapy duration from 12 months to 6 months</p>	09/01/2024

	<b>Conditions Not Covered: Removed</b> criterion regarding Atopic Dermatitis.	
Selected Revision	<p><b>Asthma:</b> Eosinophil level requirements were clarified to require a level <math>\geq</math> 150 cells/microliter either within the previous 6 weeks OR prior to treatment with a monoclonal antibody that may alter eosinophil levels. Previously, criteria required a level <math>\geq</math> 150 cells/microliter either within the previous 6 weeks OR within 6 weeks prior to treatment with a monoclonal antibody that may lower eosinophil levels.</p> <p><b>Eosinophilic Granulomatosis with Polyangiitis:</b> New approval criteria for this indication were added. Initial approval criteria include an age requirement, a requirement that the patient's disease be active and non-severe, a trial of a systemic corticosteroid, an eosinophil level requirement, and specialist involvement.</p> <p>Throughout the policy, Ebglyss (lebrikizumab-lbkz subcutaneous injection) and Nemludio (nemolizumab-ilto subcutaneous injection) were added to notes as examples of monoclonal antibody therapies.</p>	12/15/2024

The policy effective date is in force until updated or retired.

---

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.